In this episode, we explore the diagnosis and management of Myasthenia Gravis, an autoimmune disorder characterized by fluctuating muscle weakness,. We break down diagnostic tools, contrasting the high sensitivity of single-fiber electromyography (SFEMG) with repetitive nerve stimulation and serological testing for AChR, MuSK, and LRP4 antibodies,,. Finally, we discuss the shifting treatment paradigm, ranging from the established role of thymectomy to the rise of targeted biologics and FcRn inhibitors for refractory cases,,.

In this episode, we explore Alpha-1 Antitrypsin Deficiency (AATD), an inherited disorder caused by mutations in the SERPINA1 gene that can lead to early-onset emphysema and liver cirrhosis. We break down the challenges of diagnosing this under-recognized condition, detailing how laboratory experts distinguish between common deficiency alleles like Z and S, as well as rare variants such as Mmalton and P, using the biochemical gold standard of isoelectric focusing. Finally, we discuss management strategies, from lifestyle changes and augmentation therapy to groundbreaking gene-editing advancements that aim to correct the underlying genetic mutation.

In this episode, we explore Tenosynovial Giant Cell Tumor (TGCT), a rare, locally aggressive neoplasm of the joint synovium driven by colony-stimulating factor 1 (CSF1) overexpression. We discuss the distinction between the localized and diffuse subtypes, noting the latter's potential for joint destruction and high recurrence rates following surgery. Finally, we cover the emergence of targeted systemic therapies, such as the CSF1R inhibitors pexidartinib and vimseltinib, for patients with severe morbidity who are not candidates for surgery.

In this episode, we explore the rapidly evolving landscape of Spinal Muscular Atrophy (SMA), a genetic neuromuscular disorder characterised by the degeneration of motor neurones due to a deficiency in the survival motor neurone (SMN) protein,. We discuss the paradigm shift from palliative care to disease-modifying interventions, highlighting the three established therapies—nusinersen, onasemnogene abeparvovec, and risdiplam—that target the underlying genetic root of the disease.

Crucially, we cover the landmark FDA approval in late 2025 of Itvisma (onasemnogene abeparvovec-brve), a new intrathecal gene replacement therapy that expands access to patients aged two years and older,. Finally, we examine the future of combination treatments, specifically the promising Phase 3 results for apitegromab, a muscle-directed therapy designed to function alongside SMN-targeted treatments to improve motor function.

In this episode, we explore the complexities of sarcoidosis, a systemic inflammatory disease characterized by the formation of non-caseating granulomas that predominantly affect the lungs and lymph nodes but can impact virtually any organ, including the heart, skin, and nervous system. We examine the elusive etiology of the disease, which likely involves a "perfect storm" of genetic susceptibility (such as HLA alleles) and environmental triggers—ranging from microbial agents and insecticides to World Trade Center dust—that drive an exaggerated immune response. We break down the diagnostic maze, emphasizing that sarcoidosis remains a diagnosis of exclusion often requiring biopsy and advanced imaging like cardiac MRI or PET scans to confirm organ involvement. Finally, we review the latest ERS and ATS clinical guidelines, which shift the treatment paradigm to focus on quality of life and preventing organ failure, balancing the use of corticosteroids with steroid-sparing alternatives like methotrexate and infliximab to mitigate long-term toxicity.

In this episode, we explore why HIV-associated wasting syndrome remains a critical health concern despite modern antiretroviral therapy, examining the metabolic factors and cytokine imbalances driving involuntary weight loss. We also discuss the FDA's June 2025 approval of lenacapavir (Yeztugo), a groundbreaking twice-yearly injectable for HIV prevention, and break down how the virus "hijacks" cellular communication channels like gap junctions and tunneling nanotubes to spread toxicity in the brain. Finally, we review essential nutritional strategies for maintaining lean body mass and managing symptoms.

In this episode, we dive into the complex world of Juvenile Idiopathic Arthritis (JIA), exploring its distinct subtypes—from the common oligoarticular form to the autoinflammatory systemic JIA. We unpack the critical link between JIA and chronic uveitis, a potentially blinding eye condition that demands rigorous screening, and review the latest American College of Rheumatology guidelines shifting away from NSAID monotherapy toward early, aggressive biologic treatments. Finally, we discuss long-term outcomes, highlighting that while remission rates have improved, challenges like leg length discrepancy and persistent disease activity often remain into adulthood.

In this episode, we explore the genetic landscape of Y-chromosome microdeletions, a leading cause of male infertility affecting the Azoospermia Factor (AZF) regions. We examine the distinct clinical outcomes for AZFa, AZFb, and AZFc deletions—ranging from complete spermatogenic failure to successful sperm retrieval via micro-TESE. Finally, we discuss the critical role of genetic counseling regarding vertical transmission to sons and emerging links to broader male health issues like cardiovascular disease and cancer.

In this episode, we examine pouchitis, the most frequent long-term complication following ileal pouch-anal anastomosis (IPAA) surgery for ulcerative colitis, affecting up to 80% of patients. We break down the 2024 AGA Clinical Practice Guidelines, covering the use of antibiotics for intermittent symptoms and the shift toward advanced immunosuppressive therapies—such as vedolizumab—for chronic, antibiotic-refractory cases. Finally, we explore the condition's complex pathogenesis, ranging from microbial dysbiosis to immune dysregulation, and discuss essential diagnostic tools like the Pouchitis Disease Activity Index (PDAI) and pouchoscopy to rule out mimics like cuffitis or Crohn’s-like disease of the pouch.

In this episode, we explore the evolving landscape of invasive fungal diseases, dissecting the impact of the revised 2020 EORTC/MSGERC diagnostic criteria and the newly established FUNDICU definitions for critically ill patients. We also examine the rising threat of azole-resistant Aspergillus, updated 2025 guidelines for treating Aspergillosis and Histoplasmosis, and the specific infection risks associated with modern immunotherapies like JAK inhibitors.